ArticleAnimal models and experimental medicine2025
Diosgenin ameliorates silica-induced tuberculosis in rats.
Article in Animal models and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diosgenin ameliorates silica-induced tuberculosis in rats.Animal models and experimental medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSilicosis is an occupational lung disease that is caused by chronic exposure to silica dust. Silica-exposed workers are at higher risk of developing TB, resulting in lung fibrosis and significant respiratory dysfunction. Diosgenin is a steroidal saponin that has been shown to exert a therapeutic effect on lung injury. Therefore, we investigated the potential efficacy of diosgenin in treating silicotuberculosis by evaluating its effectiveness against Mycobacterium smegmatis, as well as its antifibrotic and antioxidant effects in silica-induced TB in rats.
methodsSilicosis was induced by intratracheal instillation of 50 mg/kg crystalline silica in Sprague-Dawley rats. Rats were grouped into 7 (10 per group). Different doses of diosgenin (1, 10, and 20 mg/kg) and saline were administered for 30 days. Afterwards, five rats from each group were sacrificed, and the five remaining rats in each group, except the control, received Mycobacterium smegmatis. Treatment continued until the 50th day, and the animals were sacrificed at the end of the experiment. The result was analyzed using a one-way analysis of variance (ANOVA) with GraphPad Prism.
resultsAt a half-maximal inhibition concentration of 0.006043 μg/mL, diosgenin inhibited the growth of Mycobacterium smegmatis. Oxidative stress markers such as malondialdehyde were significantly reduced. The health-enhancing effects of catalase and superoxide dismutase were elevated. Additionally, histological findings demonstrated a significant improvement in respiratory function following diosgenin treatment.
conclusionDiosgenin treatment inhibited the growth of Mycobacterium smegmatis, leading to a reduction in the susceptibility of rats to infection and improved pulmonary function through its antioxidant effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.